SaschaA.TuchmanMDMHS

Associate Professor; Director of Multiple Myeloma and Amyloidosis Program; Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill

Join to view full profile

Dr. Tuchman is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Tuchman's full profile

Already have an account?

Office
101 Manning Dr
Chapel Hill, NC 27514
Phone+1 984-974-0000

Fax+1 984-974-8612
Is this information wrong?

Education & Training

Duke University School of MedicineMHS, Clinical Research Training Program, 2008 - 2016
Duke University HospitalFellowship, Hematology and Medical Oncology, 2006 - 2010
Duke University HospitalResidency, Internal Medicine, 2003 - 2006
Georgetown University School of MedicineClass of 2003

Certifications & Licensure

NC State Medical License 2003 - 2025
American Board of Internal Medicine Hematology
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2013

Clinical Trials

Velcade + Cyclophosphamide in Newly Diagnosed Multiple Myeloma Start of enrollment: 2012 Dec 19
Terminated
Phase 2
Geriatric Assessments in Senior Adults With Multiple Myeloma Start of enrollment: 2012 Sep 01
Completed
A Phase I Study Of Panobinostat/Lenalidomide/Bortezomib/Dex for Relapsed And Relapsed/Refractory Multiple Myeloma Start of enrollment: 2013 Oct 01
Completed
Phase 1
The PRONTO Study, a Global Phase 2b Study of NEOD001 in Previously Treated Subjects With Light Chain (AL) Amyloidosis Start of enrollment: 2016 Mar 01
Completed
Phase 2
Registry for Adults With Plasma Cell Disorders (PCD's) Start of enrollment: 2018 Feb 09
Recruiting
Join now to see all

Publications & Presentations

PubMed

48 citations
Integrated safety profile of selinexor in multiple myeloma: experience from 437 patients enrolled in clinical trials
Maria Gavriatopoulou, Ajai Chari, Christine Chen, Nizar J. Bahlis, Dan T. Vogl
Leukemia. 2020-02-24
72 citations
Age-specific differences in oncogenic pathway dysregulation and anthracycline sensitivity in patients with acute myeloid leukemia.
Arati V. Rao, Peter J. M. Valk, Klaus H. Metzeler, Chaitanya R. Acharya, Sascha A. Tuchman
Journal of Clinical Oncology. 2009-11-20
65 citations
Safety and efficacy of targeting CD138 with a chimeric antigen receptor for the treatment of multiple myeloma
Chuang Sun, Aruna Mahendravada, Brandon Ballard, Brandon Kale, Carlos A. Ramos
Oncotarget. 2019-03-22

Abstracts/Posters

Response to Therapy and the Effectiveness of Treatment with Selinexor and Dexamethasone in Patients with Penta-Exposed Triple-Class Refractory Myeloma Who Had Plasmacy...
Sascha A Tuchman, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Safety and Efficacy of the Combination of Selinexor, Lenalidomide and Dexamethasone (SRd) in Patients with Newly Diagnosed Multiple Myeloma
Sascha A Tuchman, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
A Phase 1b/2 Study of Selinexor, Carfilzomib, and Dexamethasone (SKd) in Relapsed/ Refractory Multiple Myeloma (RRMM)
Sascha A Tuchman, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Geriatric Assessment and Frailty Changes in Older Patients with Newly-Diagnosed Multiple Myeloma Undergoing Treatment
Sascha A Tuchman, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Influence of Cytogenetics in Patients with Relapsed Refractory Multiple Myeloma Treated with Oral Selinexor and Dexamethasone: A Post-Hoc Analysis of the STORM Study
Sascha A Tuchman, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Join now to see all